The Limited Times

Now you can see non-English news...

Covid-19: German CureVac abandons its first vaccine candidate


The German laboratory CureVac announced on Tuesday the abandonment of the development of its first candidate vaccine against Covid-19, initially a carrier ...

The German laboratory CureVac announced Tuesday the abandonment of the development of its first candidate vaccine against Covid-19, initially hopeful but whose effectiveness has proved disappointing, to focus on a new, more promising serum.

The company specializing in messenger RNA will "

focus on the development of a vaccine against Covid-19 on the second generation

" on which it is working with the British GSK and will therefore "


" the current candidate from the procedure continuous review by the European Medicines Agency (EMA).

Read alsoCovid-19: CureVac's vaccine candidate effective at only 48%

This "

puts an end

" to the pre-order agreement for 405 million doses with the European Union, specifies the laboratory, which however continues discussions with Brussels on the second generation of vaccine.


The global fight against Covid-19 continues and we are determined to make a decisive contribution to it with a safe and effective vaccine

" but "

the requirements for an effective fight against the virus and the variants that appear have changed

", explained Franz -Werner Haas, boss of CureVac, in a statement.

48% efficiency

The German laboratory announced in early July the final results of its large-scale clinical study which showed an efficacy of only 48%, a rate much lower than other mRNA vaccines from the Pfizer / BioNTech and Moderna alliance.

CureVac and GSK want to launch “

in the coming months

” the clinical study on the second-generation vaccine, which takes more into account the variants, for approval “in the

course of 2022


An authorization for the first vaccine would also have been probable "

at the earliest in the second quarter

" of next year, the statement said.

Read alsoCovid-19: the vaccine of the German CureVac facing delays


We welcome the fact that CureVac is focusing on the promising second generation vaccine

", called CV2CoV, for which the first studies show "

a clear improvement

" compared to the first candidate, CVnCoV, affirms Rino Rappuoli, scientific director of GSK.

The biotech founded in 2000 by researcher Ingmar Hoerr, a pioneer in messenger RNA research, was among the first to embark on the vaccine race.

Source: lefigaro

All business articles on 2021-10-12

You may like

Trends 24h

Business 2021-12-02T05:12:08.226Z


© Communities 2019 - Privacy